Endomatic
Endovascular Left Atrial Appendage Closure Device
Company Overview
Snapshot
Founded in June 2018 by Boaz Schwarz, Endomatic operates with 1–10 employees. The company has raised $1M across four funding rounds from one investor. In August 2025, Endomatic secured funding from Peregrine Ventures.
Business overview
Endomatic is a Health Tech & Life Sciences company focused on developing a breakthrough endovascular Left Atrial Appendage (LAA) closure device to prevent strokes. The company's patented technology aims to eliminate the risk of device-related thrombus (DRT), a significant concern in current LAA occlusion procedures, by offering a non-thrombogenic solution. Endomatic operates within the medical devices sector, specifically targeting medical treatment and therapeutics, and serves healthcare providers.
Company Intelligence Q&A
- What is Endomatic's core technology?
- Endomatic develops a patented endovascular Left Atrial Appendage (LAA) closure device designed to prevent strokes. This technology aims to eliminate the risk of device-related thrombus (DRT) due to its non-thrombogenic nature.
- When was Endomatic founded?
- Endomatic was founded in June 2018.
- Who is the founder of Endomatic?
- Boaz Schwarz is the Co-founder & CEO of Endomatic.
- Which investor has supported Endomatic?
- Peregrine Ventures has invested in Endomatic, participating in funding rounds in January 2023, March 2024, September 2024, and August 2025.